Bank Of Montreal Tg Therapeutics, Inc. Transaction History

Bank Of Montreal

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$13.02 - $21.3 $633,748 - $1.04 Million	48,675 New	48,675 $740,000
Q2 2023 Aug 02, 2023	SELL	$15.48 - $35.0 $1.76 Million - $3.99 Million	-113,898 Reduced 47.1%	127,933 $3.18 Million
Q1 2023 Jun 13, 2024	BUY	$10.23 - $19.34 $691,077 - $1.31 Million	67,554 Added 138.79%	116,229 $1.75 Million
Q4 2022 Feb 01, 2023	BUY	$5.01 - $11.83 $776,444 - $1.83 Million	154,979 Added 178.44%	241,831 $2.86 Million
Q3 2022 Nov 10, 2022	BUY	$4.57 - $8.4 $15,542 - $28,568	3,401 Added 4.08%	86,852 $546,000
Q2 2022 Aug 11, 2022	BUY	$3.74 - $10.66 $721 - $2,057	193 Added 0.23%	83,451 $366,000
Q1 2022 May 12, 2022	BUY	$7.81 - $20.45 $42,806 - $112,086	5,481 Added 7.05%	83,258 $820,000
Q4 2021 Feb 11, 2022	SELL	$15.2 - $35.51 $12,144 - $28,372	-799 Reduced 1.02%	77,777 $1.53 Million
Q3 2021 Nov 12, 2021	SELL	$21.78 - $40.45 $9,408 - $17,474	-432 Reduced 0.55%	78,576 $2.65 Million
Q2 2021 Aug 12, 2021	BUY	$32.5 - $48.96 $2.57 Million - $3.87 Million	79,008 New	79,008 $3.12 Million

287

91.8M

1.9M

1.45M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $3.46B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.